This involves combining polysomnography (PSG), cerebrospinal fluid Aβ42/tau ratio, and dynamic contrast-enhanced MRI (DCE-MRI) glymphatic activity indicators to further build an AD risk prediction model. The gene discussed is MAPT; the disease is Alzheimer disease.